| Literature DB >> 34162331 |
Nasrin Hafezparast1, Ellie Bragan Turner1, Rupert Dunbar-Rees1, Alice Vodden1, Hiten Dodhia2, Brian Reynolds3, Barbara Reichwein4, Mark Ashworth5.
Abstract
BACKGROUND: Defining multimorbidity has proved elusive in spite of attempts to standardise definitions. For national studies, a broad definition is required to capture national diversity. For locally based studies, the definition may need to reflect demographic and morbidity patterns. We aimed to define multimorbidity for an inner city, multi-ethnic, deprived, young age community typical of many large cities.Entities:
Mesh:
Year: 2021 PMID: 34162331 PMCID: PMC8223362 DOI: 10.1186/s12875-021-01477-x
Source DB: PubMed Journal: BMC Fam Pract ISSN: 1471-2296 Impact factor: 2.497
Sources reviewed in analysis of national and international consensus on the definition of LTCs
Report on multiple LTCs [ | LTC registers [ | Chronic Ambulatory Care Sensitive LTCs indicator [ |
Self-reported LTCs (survey) [ | Self-reported LTCs (research study) [ | Compendium of Information on LTCs [ |
LTC segment definition [ | LTC management [ | LTC report [ |
Chronic disease report [ | Segment definition (Living with Illness and Chronic Conditions) [ | Report on non-communicable diseases [ |
Paper on LTCs/multimorbidity [ | Paper on LTCs/multimorbidity [ | Briefing on LTCs/multimorbidity [ |
Definition of chronic conditions [ | Definition of chronic conditions [ | LTC data packs [ |
Target criteria set for each evaluation domain
Purpose: to identify high prevalence conditions (that impact a greater number of people) | Estimated condition prevalence (UK 2017) | > = 1% |
Purpose: to identify conditions that have a greater impact on people’s lives | Progressive natural course? (yes/no) | Yes |
Purpose: to identify conditions that are having a greater population-level impact in terms of years of life lost | Rank by volume of YLL (UK, 2017—Source: GBD) | Top 20 |
Purpose: to identify conditions that are having a greater population-level impact in terms of years lived in disability | Rank by volume of YLD (UK, 2017—Source: GBD) | Top 20 |
Purpose: to identify conditions that can be prevented, the onset delayed, or improved by modifying risk factors or intervention | Do risk factors play a role in preventing or delaying the onset of the condition? (yes/no) | Yes |
| Can intervention result in complete resolution? (yes/no) | Yes | |
Purpose: to identify conditions that account for a high-proportion of population-level admitted patient care | Rank by volume of hospital admissions (based on primary diagnosis) (England, 2017/18—Source: HES data, NHSD) | Top 20 |
Purpose: to identify conditions that have a high treatment burden, particularly in relation to medication burden | Number of first-line, self-administered medications | > = 2 |
Purpose: to identify conditions that are most likely to be involved in a mLTCs journey | Proportion of people with the condition who have 1 + comorbidities | > 50% |
Purpose: to identify conditions that can present in younger people, as these that are more likely to be the first condition in a multimorbidity pathway | Typical age of onset of the condition | < 50 years old |
Purpose: to identify conditions that have a high population-level impact on years lived with disability, in younger people | Rank by volume of YLD, in people aged 15–49 (UK, 2017—Source: GBD) | Top 20 |
Purpose: to identify conditions where data quality is of a sufficient level to allow for meaningful data analysis | Level of data quality: Low/Medium/High, based on three main criteria (whether a condition is included in QOF, whether regular/frequent prescriptions are required, whether hospitalisation for the condition is common), in combination with background knowledge on data quality | Medium and High |
Fig. 1Process of evaluation of LTCs for inclusion in the definition of multimorbidity
Summary of low consensus LTCs based on literature search, including those locally important considered for inclusion in the definition of multimorbidity (n = 47)
| ‘Medication Abuse’ | |
| Memory Disturbance | |
| Bowel Incontinence | Motor Neurone Disease (MND) |
| Bronchiectasis | |
| Cerebral Palsy | |
| Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME) | Other Facial Pain |
| Chronic Sinusitis | |
| Chronic Skin Ulcer | Substance dependence |
| Constipation | |
| Cystic Fibrosis | |
| Diverticular Disease/Diverticulitis | Polio |
| ‘Drug Abuse’ | |
| Dyspepsia | Prostate Disorders |
| Eczema | Psoriasis |
| Endometriosis | Rare Long-Term Neurological LTCs |
| Frailty | |
| Gout | ‘Tobacco Abuse’ |
| Tooth Decay | |
| High Cholesterol | Trigeminal Neuralgia |
| Urinary Incontinence | |
| Irritable Bowel Syndrome (IBS) | Urinary System LTCs |
LTCs in highlighted in bold (n = 16) were considered locally important and included for further evaluation
Summary of high, medium and low consensus LTCs considered for inclusion in the definition of multimorbidity based on target criteria
| Blindness/Severe Visual Impairment | Anorexia or Bulimia | |
| Back Pain | ||
| Headache | ||
| Deafness/Severe Hearing Impairment | ||
| Migraines | ||
| Obsessive–Compulsive Disorder (OCD) | ||
| Other Inflammatory Polyarthropathies & Systemic Connective Tissue Disorders | ||
| Personality Disorder | ||
| Phobias | ||
| Post-Traumatic Stress Disorder | ||
| Thyroid Problems | ||
aAll high consensus LTCs (n = 13) met the target criteria score and included for further evaluation
bThe medium consensus LTCs highlighted in bold (n = 12) met the target criteria score and included for further evaluation
cThe low consensus LTCs highlighted in bold (n = 7) were considered locally important and included for further evaluation
Fig. 2Final list of LTCs included in definition of multimorbidity
Fig. 3Graphic of LTCs included in definition of multimorbidity